Revumenib Displays Activity in Relapsed/Refractory KMT2Ar Acute Leukemias
Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.
Related Articles
Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL
Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.
Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.
Así es la impresionante cueva de Portocolom amenazada por una promoción inmobiliaria de lujo
Es una de las más extensas de España con entrada submarina
Northwestern University Nervous System Tumor Bank
The Northwestern University Nervous System Tumor Bank provides scientists with high-quality, patient-derived biospecimens to support preclinical and translational neuro-oncology research.
Disitamab Vedotin Shows Early Efficacy in HER2-Expressing Breast Cancer With PAM Pathway Abnormalities
Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.
Polygenic risk scores and prostate cancer
Research by Fred Hutch Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active Surveillance Study (PASS), suggests that a patient’s…
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020
This model-based study using population-level cancer mortality data evaluates the association of prevention, screening, and treatment interventions with cumulative number of cancer deaths averted from…
TRANSCEND CLL 004 Analysis Proposes Meaningful Change Thresholds for PRO Measures in R/R CLL
Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.